ACE2 and diabetic complications

Current Pharmaceutical Design

Volumn 13, Issue 26, 2007, Pages 2730-2735

  Dean, Rachael G ^a   Burrell, Louise M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

ACE2; Atherosclerosis; Diabetes mellitus; Myocardial infarction; Nephropathy; Renin angiotensin system; Retinopathy

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; ANGIOTENSIN V; ANGIOTENSIN VI; ANGIOTENSIN VII; ATENOLOL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG SYNTHESIS; ENZYME ACTIVITY; HEART; HEART DISEASE; HUMAN; HYPERTENSION; HYPERTROPHY; KIDNEY PARENCHYMA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASOCONSTRICTION; VASODILATATION;

ANGIOTENSIN II; ANIMALS; DIABETES COMPLICATIONS; HEART DISEASES; HUMANS; KIDNEY DISEASES; PEPTIDYL-DIPEPTIDASE A;

EID: 34548788569     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781662876     Document Type: Review

References (57)

1. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213-9.
2. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
3. Lewis EJ, Hunsicker LG, Clarke WF, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
4. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 1004-10.
5. Johnston CI. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension 1994; 23: 258-68.
6. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-E9.
7. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme - cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275: 33238-43.
8. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension 1997; 30: 535-41.
9. Turner AJ. Exploring the structure and function of zinc metallopeptidases: Old enzymes and new discoveries. Biochem Soc Trans 2003; 31: 723-7.
10. Oudit GY, Crackower MA, Backx PH, Penninger JM. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med 2003; 13: 93-101.
11. Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 2005; 26: 369-75; discussion 322-4.
12. Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003; 41: 392-7.
13. Brosnihan KB, Neves LA, Joyner J, Averill DB, Chappell MC, Sarao R, et al. Enhanced renal immunocytochemical expression of ANG-(1-7) and ACE2 during pregnancy. Hypertension 2003; 42: 749-53.
14. Tikellis C, Johnston CI, Forbes JM, Burns WC, Thomas MC, Lew RA, et al. Identification of angiotensin converting enzyme 2 in the rodent retina. Curr Eye Res 2004; 29: 419-27.
15. Paizis G, Tikellis C, Cooper ME, Schembri JM, Lew RA, Smith AI, et al. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut 2005; 54: 1790-6.
16. Harmer D, Gilbert M, Borman R, Clark K. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 2002; 532: 107-10.
17. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002; 277: 14838-43.
18. Duka I, Kintsurashvili E, Gavras I, Johns C, Bresnahan M, Gavras H. Vasoactive potential of the B-1 bradykinin receptor in normotension and hypertension. Circulation Research 2001; 88: 275-81.
19. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-8.
20. Donoghue M, Wakimoto H, Maguire CT, Acton S, Hales P, Stagliano N, et al. Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins. J Mol Cell Cardiol 2003; 35: 1043-53.
21. Huang L, Sexton DJ, Skogerson K, Devlin M, Smith R, Sanyal I, et al. Novel peptide inhibitors of angiotensin-converting enzyme 2. J Biol Chem 2003; 278: 15532-40.
22. Dales NA, Gould AE, Brown JA, Calderwood EF, Guan B, Minor CA, et al. Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. J Am Chem Soc 2002; 124: 11852-3.
23. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1-7): An evolving story in cardiovascular regulation. Hypertension 2006; 47: 515-21.
24. Tallant EA, Clark MA. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 2003; 42: 574-9.
25. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100: 8258-63.
26. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 2005; 289: H1560-6.
27. Castro CH, Santos RA, Ferreira AJ, Bader M, Alenina N, Almeida AP. Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. Hypertension 2005; 46: 937-42.
28. Cooper ME, Johnston CI. Optimizing treatment of hypertension in patients with diabetes. JAMA 2000; 283: 3177-9.
29. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-62.
30. Brenner BM. Retarding the progression of renal disease. Kidney Int 2003; 64: 370-8.
31. Ferrario CM. Commentary on Tikellis et al: There is more to discover about angiotensin-converting enzyme. Hypertension 2003; 41: 390-1.
32. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Ratlle D. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: A renoprotective combination? Hypertension 2004; 43: 1120-5.
33. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-13.
34. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003; 92: 785-92.
35. Dean RG, Balding LC, Candido R, Burns WC, Cao Z, Twigg SM, et al. Connective tissue growth factor and cardiac fibrosis after myocardial infarction. J Histochem Cytochem 2005; 53: 1245-56.
36. Yagil Y, Yagil C. Hypothesis: ACE2 modulates blood pressure in the mammalian organism. Hypertension 2003; 41: 871-3.
37. Candido R, Srivastava P, Cooper ME, Burrell LM. Diabetes mellitus: A cardiovascular disease. Curr Opin Investig Drugs 2003; 4: 1088-94.
38. Grundy SM, Howard B, Smith S, Jr., Eckel R, Redberg R, Bonow RO. Prevention Conference VI: DiabeEes and Cardiovascular Disease: executive summary: Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002; 105: 2231-9.
39. Srivastava PM, Thomas MC, Calafiore P, MacIsaac RJ, Jerums G, Burrell LM. Diastolic dysfunction is associated with anaemia in patients with Type II diabetes. Clin Sci (Lond) 2006; 110: 109-16.
40. Dean RG, Nordkamp M, Burchill LJ, Griggs K, Tikellis C, Lu S, et al. ACE2, a target for diabetic heart disease? Heart Foundation Conference and Scientific Meeting. Sydney, NSW, 2006; 23.
41. Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 2005; 90: 783-90.
42. Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1-7) prevents cardiac fibrosis in the DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 2006; 290(6): H2417-23.
43. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
44. Candido R, Allen TJ, Lassila M, Cao Z, Thallas V, Cooper ME, et al. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 2004; 109: 1536-42.
45. Zulli A, Burrell LM, Widdop RE, Black MJ, Buxton BF, Hare DL. Immunolocalization of ACE2 and AT2 receptors in rabbit atherosclerotic plaques. J Histochem Cytochem 2006; 54: 147-50.
46. Duncan AM, Burrell LM, Campbell DC. Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction. J Cardiovasc Pharmacol 1996; 28: 746-54.
47. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000; 35: 569-82.
48. Goulter AB, Goddard MJ, Allen JC, Clark KL. ACE2 gene expression is up-regulated in the human failing heart. BMC Med 2004; 2: 19.
49. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, et al. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: Evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation 2003; 108: 1707-12.
50. Averill DB, Ishiyama Y, Chappell MC, Ferrario CM. Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation 2003; 108: 2141-6.
51. Loot AE, Roks AJ, Henning RH, Tio RA, Suurmeijer AJ, Boomsma F, et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002; 105: 1548-50.
52. Santos RA, Ferreira AJ, Nadu AP, Braga AN, de Almeida AP, Campagnole-Santos MJ, et al. Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats. Physiol Genomics 2004; 17: 292-9.
53. Sjolie AK, Chaturvedi N. The retinal renin-angiotensin system: implications for therapy in diabetic retinopathy. J Hum Hypertens 2002; 16(Suppl 3): S42-6.
54. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of lisinopril in insulin-dependent diabetes mellitus. Lancet 1998; 351: 28-31.
55. Luno J, Praga M, de Vinuesa SG. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS). Curr Pharm Des 2005, 11(10): 1291-300.
56. Onder G, Vedova CD, Pahor M. Effects of ACE inhibitors on skeletal muscle. Curr Pharm Des 2006; 12(16): 2057-64.
57. Shimada Y. Does Angiotensin converting enzyme inhibitor protect the heart in cardiac surgery? From laboratory to operating room: Clinical application of experimental study. Curr Pharm Des 2006; 12(4): 517-26